Accession Number : ADA266829


Title :   Development of Safe, Effective Vaccines for Dengue Virus Disease by Recombinant Baculovirus


Descriptive Note : Interim rept. 1 Mar 92-29 Feb 93,


Corporate Author : NATIONAL INSTITUTES OF HEALTH BETHESDA MD


Personal Author(s) : Lai, Ching J


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a266829.pdf


Report Date : 01 Apr 1993


Pagination or Media Count : 4


Abstract : In our previous Annual Report, covering the period 3/1/91-2/28/92, we described our finding that cells infected with recombinant baculovirus expressing the 80% N-terminal protein of the dengue virus envelope (E) glycoprotein secreted the 80%E protein into the surrounding medium. This property was unique for recombinant baculoviruses containing the dengue E gene constructed in this laboratory. Viruses containing this E fragment from dengue type 2, 3, or 4 were designated b (DENZ,80%), b(DEN3, 80%) or b(DEN4, 80%), respectively. Mice inoculated with the secreted DEN4 80%E protein in partially concentrated medium developed a stronger antibody response to DEN4 E as determined by Western blotting, than did mice inoculated with lysates of cells infected with b(DEN4, 80%E) or with previously constructed recombinants b(DEN 4, 93%), b(DEN4, C-preM-E-NSI-NS2A), or b(DEN4, RSVG-E). Since the dengue virus protein products of the latter two recombinants appeared to partially protect rhesus monkeys against challenge with wild-type DEN4 virus in an earlier experiment, we decided to test b(DEN4, 80%E) in a second monkey experiment, to see if we could obtain a more convincing protective response.


Descriptors :   *VACCINES , *DENGUE VIRUS , PROTEINS , GLYCOPROTEINS , GENES , LYOPHILIZATION , INFECTIOUS DISEASES , MEDICAL RESEARCH , IMMUNIZATION


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE